Redx Pharma
Alderley Edge, United Kingdom

Redx Pharma specialises in the discovery and development of small molecule therapeutics, with an emphasis on oncology and fibrotic disease. It aims to initially progress them through proof-of-concept studies, before evaluating options for further development and value creation. Existing earlier-stage collaboration partners include AstraZeneca and Jazz Pharmaceuticals.

Investment Perspective

Redx Pharma’s two lead assets are in Phase II trials and key data for both are expected during H223. These are RXC004, a porcupine inhibitor for Wnt-ligand dependent solid tumours, and RXC007, a ROCK2 inhibitor in IPF (idiopathic pulmonary fibrosis). Efficacy insights from both datasets should provide valuable information on the commercial potential of each candidate and visibility on next steps. Redx Pharma has discovered and developed five molecules which are currently in clinical trials, and the discovery engine and differentiated medicinal chemistry expertise continue to bear fruit, with a growing earlier stage preclinical pipeline. This includes RXC008, a GI targeted ROCK inhibitor, which is progressing towards IND/CTA submission by end-2023 for fibrostenotic Crohn’s disease. Cash resources should be sufficient through key H223 value inflection points. Our rNPV-based valuation is £461m (from £458m), or 138p/share.

Market information

SymbolPrimary exchanges


Key Phase II data for lead assets expected during H223
Update | 30 Jan 2023
Laying the foundations for further delivery in 2023
Lighthouse | 20 Dec 2022
New data draws attention to promising fibrosis assets
Update | 07 Oct 2022

Recent News

FY22 Results
20 Dec 2022
Clinical trial agreement with MSD
16 Dec 2022
Poster to be presented at IBD Nordic Conference
17 Nov 2022
RXC004 Phase II combination arms to open enrolment
10 Nov 2022